Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 6/20 | 0.40 |
| ▸ | STK17B | O94768 | 4/20 | 0.40 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021252 | 0.99 | STK17A (0.39) | STK17ASTK17BFERMT2NPC1RAB9A | |
| SCHEMBL1020741 | 0.99 | STK17A (0.39) | STK17ASTK17BFERMT2NPC1RAB9A | |
| SCHEMBL1022893 | 0.96 | STK17A (0.40) | STK17ASTK17BFERMT2NPC1RAB9A | |
| SCHEMBL1020371 | 0.91 | NPC1 (0.39) | STK17AFERMT2NPC1RAB9AALDH1A1 | |
| SCHEMBL1021808 | 0.87 | ALDH1A1 (0.35) | STK17ASTK17BALDH1A1 | |
| SCHEMBL1021399 | 0.87 | SYK (0.38) | NPC1RAB9AALDH1A1LMNACYP1A2 | |
| SCHEMBL1021459 | 0.86 | MAOA (0.38) | — | |
| SCHEMBL1019082 | 0.86 | DYRK1B (0.36) | STK17ASTK17BALDH1A1 | |
| SCHEMBL1020759 | 0.86 | SYK (0.37) | NPC1RAB9AALDH1A1LMNACYP1A2 | |
| SCHEMBL1020743 | 0.86 | DYRK1B (0.36) | STK17ASTK17BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | STK17A 756/4885STK17B 616/4885FERMT2 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.